Interstitial pneumonia microenvironment promotes metastasis to the mediastinal lymph nodes and lungs [0.03%]
问性肺炎微环境促进淋巴结和肺的转移
Ryo Maeda,Mayu Inomata,Ryusei Yamada
Ryo Maeda
Introductionhta: The prognosis of patients with lung cancer and interstitial lung disease (ILD) is worse than that of patients without ILDs; however, therapeutic options for ILD-associated lung cancer are severely limited...
Pathological complete response to conversion therapy for lung adenocarcinoma with brain metastasis: a case report [0.03%]
肺腺癌伴脑转移新辅助治疗病理完全缓解1例报告
Xingqiang Ran,Tao Luo,Jie Xiong et al.
Xingqiang Ran et al.
Lung cancer is the leading cause of cancer mortality worldwide. Fortunately, the advent of precision medicine, which includes targeted therapy and immunotherapy, has significantly improved the survival rates of patients with locally advance...
Cancer outcomes of pregnancy after diagnosis of breast cancer in premenopausal women: an updated systematic review and meta-analysis [0.03%]
绝经前女性乳腺癌诊断后妊娠结局的系统综述和meta分析
Heting Mei,Qingya Song,Wenping Lu et al.
Heting Mei et al.
Introduction: Breast cancer is a type of hormone-driven cancer, and pregnancy may increase the risk of recurrence in patients due to hormone surge. Our study was designed to explore the cancer outcomes of premenopausal wo...
Anti-neoplastic effects of the antipsychotic drug penfluridol in preclinical prostate cancer models [0.03%]
抗精神病药物培氟啶在前列腺癌的临床上的抗新生物作用
Arjanneke F van de Merbel,Maaike H van der Mark,Tilly Aalders et al.
Arjanneke F van de Merbel et al.
Introduction: The development of therapy resistance and the formation of distant metastases represent clinical unmet needs for patients with advanced prostate cancer (PCa). The use of drugs for other indications, i.e. dru...
Analysis of lymph node recurrence patterns and risk factors in locally advanced esophageal carcinoma following neoadjuvant therapy [0.03%]
新辅助治疗后局部晚期食管癌淋巴结复发模式及危险因素分析
Yingxin Liu,Xiaojun Wang,Zixuan Ni et al.
Yingxin Liu et al.
Background: Although neoadjuvant therapy followed by surgery is the standard treatment for resectable locally advanced esophageal carcinoma, heterogeneity exists in neoadjuvant regimens within real-world practice. This st...
Survival outcomes of intrathoracic vs. cervical anastomosis post-esophagectomy in middle and lower thoracic esophageal squamous cell carcinoma: a retrospective propensity score matching analysis [0.03%]
食管鳞癌患者食管切除术后中下段食管吻合口位置对生存结局的影响：倾向性匹配分析
Xueqiang Wei,Jie Mao,Yuncheng Bai et al.
Xueqiang Wei et al.
Objective: This study aimed to compare long-term survival outcomes between cervical anastomosis (CA) and intrathoracic anastomosis (IA) in patients with middle and lower thoracic esophageal squamous cell carcinoma (ESCC)....
Contrast-enhanced ultrasound diagnosis and efficacy prediction of primary breast lymphoma: a case report and literature review [0.03%]
强化超声在乳腺原发性淋巴瘤诊断及疗效评估中的价值：1例报道并结合文献复习
Siqi Tang,Yuqin Ma,Xiaochen Zhan et al.
Siqi Tang et al.
Primary breast lymphoma (PBL) is a rare entity, accounting for less than 1% of all breast malignancies. PBL is often difficult to differentiate from other benign and malignant breast tumors. This case report describes the contrast-enhanced ...
The role of immune- and lipid metabolism-related genes in macrophage polarization and prognosis of glioblastoma [0.03%]
与胶质母细胞瘤巨噬细胞极化和预后相关的免疫代谢相关基因的作用研究
Yue Zhang,Xin Xu,Shuo Li et al.
Yue Zhang et al.
Objective: To investigate the roles of immune- and lipid metabolism-related genes in macrophage polarization and their prognostic and therapeutic implications in glioblastoma (GBM). ...
Case report: Von Hippel-Lindau syndrome with multisystem involvement: a therapeutic dilemma [0.03%]
病例报告：多系统受累的Von Hippel-Lindau病的治疗困境
Shuai He,Cong Wang,Jing Yang et al.
Shuai He et al.
We present a rare case of von Hippel-Lindau (VHL) syndrome type 2B, characterized by multisystem involvement including Stanford type B aortic dissection, pheochromocytoma, renal cell carcinoma (RCC), cerebellar hemangioblastoma with obstruc...
European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study [0.03%]
欧洲HER2阳性晚期/转移性乳腺癌患者通过个别病人计划接受德鲁替康治疗的使用经验：EUROPA 德鲁替康研究
Cristina Saura,Hans Wildiers,Giampaolo Bianchini et al.
Cristina Saura et al.
Introduction: In January 2021, trastuzumab deruxtecan (T-DXd) received conditional approval in the European Union for the treatment of human epidermal growth factor receptor 2-positive (HER2-positive) unresectable or meta...